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1 Contributed equally to this work.N-acetyl-L-glutamate synthase (NAGS), the ﬁrst enzyme of arginine biosynthesis in bacteria/plants
and an essential urea cycle activator in animals, is, respectively, arginine-inhibited and activated.
Arginine binds to the hexameric ring-forming amino acid kinase (AAK) domain of NAGS. We show
that arginine inhibits Pseudomonas aeruginosa NAGS by altering the functions of the distant,
substrate binding/catalytic GCN5-related N-acetyltransferase (GNAT) domain, increasing KGlum ,
decreasing Vmax and triggering substrate inhibition by AcCoA. These effects involve centrally the
interdomain linker, since we show that linker elongation or two-residue linker shortening hampers
and mimics, respectively, arginine inhibition. We propose a regulatory mechanism in which argi-
nine triggers the expansion of the hexameric NAGS ring, altering AAK–GNAT domain interactions,
and the modulation by these interactions of GNAT domain functions, explaining arginine regulation.
 2008 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
In microorganisms and plants, N-acetyl-L-glutamate synthase
(NAGS) catalyzes the ﬁrst arginine biosynthesis step and is feed-
back inhibited by arginine [1]. In contrast, in mammals, NAGS is
activated by arginine [2,3] and its product, N-acetyl-L-glutamate
(NAG), is the essential activator of the ﬁrst urea cycle enzyme, car-
bamoyl phosphate synthetase I (CPSI). Thus, NAGS deﬁciency is an
inborn error causing clinical hyperammonaemia [4].
Bacterial NAGS gene sequences (Fig. 1A; http://www.exp-
asy.org) revealed a two-domain organization of the NAGS polypep-
tide, with 280- and 150-residue N- and C-terminal domains
belonging, respectively, to the amino acid kinase (AAK) and
GCN5-related N-acetyltransferase (GNAT)-acetyltransferase fami-
lies. Since the AAK domain particularly resembles the hexameric,
arginine-inhibitable acetylglutamate kinase (NAGK) [5], and since
Escherichia coli NAGS was proven hexameric [6], bacterial NAGS
was proposed [5] to be, as NAGK, a hexameric ring of AAK domains,
formed by linking three AAK domain dimers through their inter-chemical Societies. Published by E
N5-related N-acetyltransfer-
-L-glutamate kinase; NAGS,
ginosa; Ng, Neisseria gonor-
ts with the respective linker
282QFEQ.laced N-terminal a helices. The GNAT domain is linked to the
AAK domain through a connector, and was proposed [5] to rest
on the AAK domain of an adjacent dimer (Fig. 1B). The recent deter-
mination of the crystal structure of Neisseria gonorrhoeae NAGS
(NgNAGS) (Fig. 1C) [7] conﬁrmed this architecture and revealed
the binding of AcCoA and NAG in the GNAT domain, a domain
shown by site-directed mutagenesis studies [8] to be responsible
for substrate binding and catalysis.
Using sequence comparisons and site-directed mutagenesis we
localized in Pseudomonas aeruginosa NAGS (PaNAGS) the arginine
site in the AAK domain, in the same place as in NAGK, next to
the interdimeric boundary and the N-terminal a-helix (Fig. 1B)
[8]. We clarify here, using mutant forms of PaNAGS in which the
interdomain linker (Fig. 1E) was elongated or shortened, how the
binding of the effector at its remote site (Fig. 1B) can inﬂuence
the activity of the GNAT domain. Our data support the same basic
mode of regulation by arginine as in NAGK [5]: the triggering by
the effector of hexameric ring widening and ﬂattening (Fig. 1D).
This widening would be expected to displace the GNAT domains
from their normal resting places, because of pulling mediated by
the interdomain linker ( Fig. 1C and D). In agreement with this
expectation, we ﬁnd that linker elongation hampers arginine inhi-
bition and that two-residue linker shortening mimics the effects of
arginine, which we also characterize here. These studies provide
further [8] support for a key role of the AAK domain in modulating
GNAT domain functions. Since we ﬁnd that one-residue linker
shortening can increase NAGS activity and that one-residue linkerlsevier B.V. All rights reserved.
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Fig. 1. Bacterial NAGS and its engineered forms used here. (A) Domain composition and (B) schematic architecture of bacterial NAGS showing the gross locations of the
arginine site [8] and of G146 (an AAK domain residue that, when mutated, affected KGlum and Vmax [8]) to highlight its relative locations with respect to the GNAT domain. (C)
Detail of the NgNAGS structure [7] showing the GNAT–AAK domain relations. Domains from different subunits are in different colors. Residue G148 (corresponding to G146 of
PaNAGS), is highlighted with a sphere and labelled. (D) Proposed ring expansion upon arginine binding. The arrows indicate the movements leading to ring enlargement and
ﬂattening. Note the corresponding displacement of the GNAT domains. For clarity only the three GNAT domains that are closer to the viewer are represented. (E) Interdomain
linker identiﬁcation in PaNAGS from its alignment with the NgNAGS linker, and mutations engineered into the PaNAGS linker. (F) Coomassie-stained SDS–PAGE of theWT and
mutant forms (St, molecular weight standards), and, at the bottom, activity of each enzyme form in the standard assay (mean ± S.D.).
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may underlie arginine activation of mammalian NAGS [2,3].
2. Materials and methods
PaNAGS containing the GSLEH6 C-terminal tail was puriﬁed as
described [8]. PaNAGS with the mutant linker sequences 282QEQA-
FEQ, 282QEAQAFEQ (inserted alanines are underlined), 282QEFEQ
and 282QFEQ (Fig. 1E; abbreviated +A, +2A, Q and EQ, respec-
tively) were prepared by the overlapping extension method using
a commercial kit (Quickchange, from Stratagene), the pET-22b
plasmid carrying the wild-type (WT) gene as template, and appro-
priate mutagenic forward and reverse oligonucleotides (primer se-
quences will be provided on request). Mutant puriﬁcations were as
for WT enzyme [8], using the storage and dilution solutions re-
ported in [6].NAGS activity was assayed colorimetrically with Ellman’s
reagent, as CoA release [9], as previously reported [8], except
for the use of 30 mM glutamate and 4 mM AcCoA and for the
omission of MgCl2. When the concentration of AcCoA was
varied, assay volume was increased as required, from the stan-
dard 0.02 ml, up to 0.3 ml, for higher sensitivity. Blanks without
enzyme were run in parallel and were subtracted. Color produc-
tion was linear in all assays for at least 10 min. One enzyme
unit produces 1 lmol CoA min1. Results of at least duplicate
assays were ﬁtted with GraphPadPrism (GraphPad Software,
San Diego) to either hyperbolic kinetics or to substrate inhibi-
tion kinetics [10] (v = V  [S]/(KmS + [S] + [S]2/Ki); S, substrate, v
and V, activities at a given [S] and at [S] =1; KSm, apparent Km
for S; Ki, substrate inhibition constant). Protein was determined
by the Bradford assay [11] using bovine serum albumin as
standard.
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3.1. Preparation and activity of the mutants
We identiﬁed from the sequence (Fig. 1E) the PaNAGS interdo-
main linker, and we prepared mutants (see sequences in Fig. 1E)
with 1 and 2 extra alanines (+A, +2A) or lacking one (Q) or two
(EQ) residues. These mutants were easily puriﬁed to homogene-
ity from E. coli BL21 (DE3) cells (Fig. 1F) and were active and stable,
although their speciﬁc activities were (Fig. 1F) 38%, 45% and
70% lower for +A, +2A and EQ, respectively and 45% higher
for Q, relative to WT NAGS.Table 1
Inﬂuence of linker elongation or shortening on the kinetic parameters for NAGS activity in
NAGS form [Arg] (mM) Kinetic parameters for AcCoA
KAppm (mM) V
[AcCoA] = 1 (U mg1)
WT – 0.09 ± 0.01 80 ± 1
2 0.05 ± 0.02 15 ± 2
+A – 0.10 ± 0.02 45 ± 1
2 0.14 ± 0.02 58 ± 1
+2A – 0.07 ± 0.02 42 ± 1
2 0.13 ± 0.03 50 ± 3
Q – 0.24 ± 0.04 175 ± 11
2 0.15 ± 0.04 13 ± 2
EQ – 0.26 ± 0.11 56 ± 10
2 0.22 ± 0.05 18.2 ± 1.7
Kinetic parameters were determined as indicated in Section 2, and correspond to the dat
inhibition constant in the substrate inhibition equation. Standard errors are given.
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Fig. 2. Dependency of enzyme activity on the concentrations of the substrates for the diff
2 mM arginine. When ﬁxed, AcCoA and glutamate were at respective concentrations of 4
kinetics with substrate inhibition (see Table 1 for the values of the individual constants).
presence of arginine, 0.35–1.6 and 1.1–5.5 lg ml1 (the concentrations differed for
concentration of this substrate, in the respective absence and presence of arginine, 0.04–
was independent of protein concentration (tested in the 0.04–0.61 lg ml1 range, at 1 m3.2. Linker elongation mutations decrease Vmax and hamper arginine
inhibition
The lower activity of the +A and +2A mutants resulted from
Vmax decrease (Table 1), but in all other respects these mutants
presented similar kinetics as WT NAGS, with hyperbolic plots for
AcCoA and with substrate inhibition at high glutamate concentra-
tions (Fig. 2A and B and Table 1).
As expected for arginine inhibition resulting from hexameric
ring widening (Fig. 1D), linker lengthening dramatically
hampered arginine inhibition. Whereas WT NAGS was virtually
completely inhibited by 2 mM arginine, none of these mutantsthe absence and in the presence of arginine.
Kinetic parameters for glutamate
Ki (mM) K
App
m (mM) V
[Glu] = 1 (U mg1) Ki (mM)
No inhib. 5.2 ± 1.4 136 ± 20 72 ± 36
2.4 ± 0.6 85 ± 19 22 ± 3 No inhib.
No inhib. 2.1 ± 0.2 80 ± 3 60 ± 7
No inhib. 2.2 ± 0.6 79 ± 7 78 ± 19
No inhib. 2.6 ± 1.0 70 ± 11 67 ± 37
15.1 ± 5.8 4.9 ± 2.0 60 ± 10 152 ± 89
7.9 ± 1.7 20 ± 1 192 ± 4 No inhib.
1.6 ± 0.4 106 ± 36 36 ± 8 No inhib.
3.0 ± 1.2 100 ± 5 90 ± 3 No inhib.
10.1 ± 4.4 107 ± 62 57 ± 21 No inhib.
a in Fig. 2. KAppm , apparent Km values (30 mM ﬁxed glutamate; 4 mM ﬁxed AcCoA). Ki,
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Fig. 3. Inﬂuence of arginine concentration on enzyme activity of the WT and the
mutant enzyme forms. Results are expressed as a percentage of the activity of the
same enzyme form in the absence of arginine. The standard assay containing 4 mM
AcCoA and 30 mM glutamate was used (see Section 2). When L-arginine was
replaced by D-arginine there was no inhibition (data not shown). Asterisks indicate
statistically signiﬁcant differences for mutant +A, for the different arginine
concentrations, relative to the activity in the absence of arginine (**P < 0.01, and
*P < 0.05; n = 9–12), using ANOVA, followed by the Bonferroni test for individual
points. Similar statistical analysis for mutant +2A (n = 10–14) did not yield
signiﬁcant differences.
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5 mM (Fig. 3).
Interestingly, low arginine concentrations activated, although
little, mutant +A (Fig. 3; signiﬁcant differences with respect to ab-
sence of arginine are illustrated with asterisks). An activation too
small to be statistically signiﬁcant was also observed with the
+2A mutant. The activation reﬂects the binding to these mutants
of arginine, as expected given the intactness of the arginine site.
The arginine activation appears to result from a decrease in sub-
strate inhibition by glutamate triggered by 2 mM arginine
(Fig. 2C and D; Table 1); otherwise, 2 mM arginine affected little
the substrate kinetics of these two mutants, triggering only on
the +2A mutant some substrate inhibition by AcCoA (an inhibitory
effect that was counterbalanced by the decreased substrate inhibi-
tion by glutamate). In contrast, 2 mM arginine had dramatic effects
on WT NAGS (Fig. 2C and D; Table 1), increasing 16-fold apparent
KGlum , causing substrate inhibition by AcCoA (Ki = 2.4 mM) and
reducing 60% Vmax (estimated by calculating the expected Vmax
if arginine changed only the Km and Ki values, Table 1).
3.3. Effects of linker shortening
As expected for the hexameric ring expansion model of arginine
inhibition, the EQ mutant caused on the enzyme some effects
that were similar to those caused by arginine (Fig. 2A and B; Table
1): it decreased enzyme activity, increasing the KGlum and inducing
substrate inhibition by AcCoA. Even 1-residue shortening (Q mu-
tant) increased KGlum and triggered AcCoA inhibition, (Fig. 2A and B;
Table 1). However, the Q mutant was more active in the standard
assay (Fig. 1F) and exhibited a higher Vmax than WT NAGS (Fig. 2A
and B; Table 1).
Both deletion mutants were sensitive to arginine (Fig. 3) at
similar concentration ranges than the WT enzyme. The arginine
inhibition of the EQ mutant appeared incomplete, but this was
a relative effect of the poor activity of this mutant, since its abso-
lute activity at inﬁnite arginine concentration was estimated to
be only marginally higher (2-fold higher) than for WT NAGS.
The kinetic factors responsible for arginine inhibition with these
two mutants were grossly similar as for WT NAGS (Fig. 2C and
D; Table 1).4. Discussion
The high similarity in architecture [5,7] and arginine site [5,8]
between NAGS and NAGK strongly suggest that, as with NAGK
[5], arginine triggers the expansion and ﬂattening of the hexameric
enzyme ring (Fig. 1D). Since in NAGS the substrates bind and catal-
ysis proceeds in a separately folded GNAT domain [7,8], arginine-
triggered overall ring changes must affect GNAT domain functions
by altering the interactions of this domain with the AAK domain.
These interactions were previously proven to be important [8].
Ring expansion should drag the GNAT domain out of its normal po-
sition on the AAK domain (Fig. 1D). Therefore, linker lengthening
should alleviate this drag and should hamper arginine inhibition,
whereas linker shortening should mimic arginine in dragging out
of position the GNAT domain. These two predictions have been ful-
ﬁlled in our experiments, which thus provide support for this
mechanism of regulation, in addition to revealing a key role of
the interdomain linker in the intramolecular transduction of the
arginine signal.
Arginine is found here to alter NAGS activity by a multiplicity of
effects. It increases KGlum , it elicits and prevents substrate inhibition
by, respectively, AcCoA and by glutamate, and it decreases Vmax.
The NgNAGS structure ([7] and Fig. 1C) provides clues on how
small changes in GNAT–AAK domain interactions can trigger these
effects. This is particularly clear concerning glutamate, since its c-
COO is bound to Arg425 and its binding pocket wall includes res-
idues 390–392, two elements that are adjacent to residues
(Thr393, Asn394, Asn426 and His428) which anchor the GNAT do-
main on the AAK domain. Similarly, it is conceivable that arginine,
by altering the position of the GNAT domain, might make extra
room between the surfaces of the AAK and GNAT domains that
sandwich the phophoadenosine moiety of the AcCoA molecule
[7], possibly allowing aberrant AcCoA conformations that result
in non-productive complexes and in substrate inhibition by AcCoA.
Finally, the inﬂuence of arginine on the Vmax can be explained if kcat
is determined by conformational changes associated with the
opening and closing of the active centre (a likely possibility, in
view of the deepness of the acetyl group transfer site [7]). Given
the intimate contact between both domains, it is conceivable that
small changes in the interactions may hamper or facilitate active
site opening/closing in the GNAT domain.
Our demonstration that the Vmax can be augmented by one-res-
idue shortening (Q mutant), most likely because of altered inter-
domain interactions, and our observation that arginine can become
an activator (although modest) by simply adding one residue (+A)
to the linker, may be relevant for understanding arginine activation
of NAGS in land vertebrates [2,3,12]. In fact, even in the case of
mammalian NAGS, arginine has a dual role, being an activator at
low concentration, and inhibiting the enzyme at higher concentra-
tion [2]. Our results suggest that not much change appears neces-
sary in NAGS for shifting the effects of arginine from inhibition to
activation, as observed in the transition from marine life forms to
land tetrapods.Acknowledgements
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